We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

252 hedge funds and large institutions have $4.58B invested in Iovance Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 83 increasing their positions, 91 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $52.7M | Put options by funds: $26.5M

18% more capital invested

Capital invested by funds: $3.88B → $4.58B (+$704M)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

0.67% less ownership

Funds ownership: 96.25% → 95.58% (-0.67%)

9% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 91

10% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 51

2% less funds holding

Funds holding: 257 → 252 (-5)

Holders
252
Holders Change
-5
Holders Change %
-1.95%
% of All Funds
5.08%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
46
Increased
83
Reduced
91
Closed
51
Calls
$52.7M
Puts
$26.5M
Net Calls
+$26.2M
Net Calls Change
-$19.2M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$112M
2
Franklin Resources
Franklin Resources
California
+$41.6M
3
NAMA
Nikko Asset Management Americas
New York
+$23.5M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$23.3M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$13.4M

Top Sellers

1
PA
Perceptive Advisors
New York
-$52.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$30M
3
ACA
Avoro Capital Advisors
New York
-$25.3M
4
EAM
Eagle Asset Management
Florida
-$19.8M
5
Goldman Sachs
Goldman Sachs
New York
-$18.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Man Group
251
Man Group
United Kingdom
– -$6.47M -235,704 Closed
BC
252
Boxer Capital
California
– -$5.49M -200,000 Closed
HF
253
HRT Financial
New York
– -$3.08M -112,098 Closed
Arrowstreet Capital
254
Arrowstreet Capital
Massachusetts
– -$2.94M -107,247 Closed
EI
255
EAM Investors
California
– -$1.46M -53,143 Closed
LCM
256
Laurion Capital Management
New York
– -$1.36M -49,495 Closed
PM
257
Precept Management
Texas
– -$1.24M -45,000 Closed
CAM
258
ClariVest Asset Management
California
– -$1.34M -43,871 -100%
VC
259
Voss Capital
Texas
– -$1.1M -40,000 Closed
PCM
260
Pinz Capital Management
New York
– -$1.08M -39,200 Closed
AC
261
Athanor Capital
New York
– -$1.01M -36,895 Closed
Tudor Investment Corp
262
Tudor Investment Corp
Connecticut
– -$877K -31,938 Closed
RIA
263
Realta Investment Advisors
Delaware
– -$854K -31,115 Closed
AG
264
Algert Global
California
– -$844K -30,757 Closed
MSL
265
Mackay Shields LLC
New York
– -$659K -24,000 Closed
SAM
266
Sectoral Asset Management
Quebec, Canada
– -$571K -20,800 Closed
GIA
267
Gladstone Institutional Advisory
Florida
– -$473K -17,223 Closed
DC
268
Diametric Capital
Massachusetts
– -$471K -17,156 Closed
TRSOTSOK
269
Teachers Retirement System of the State of Kentucky
Kentucky
– -$434K -15,825 Closed
RCG
270
Rock Creek Group
District of Columbia
– -$412K -15,000 Closed
KAS
271
Kemnay Advisory Services
New York
– -$403K -14,685 Closed
DTL
272
Dynamic Technology Lab
Singapore
– -$358K -13,051 Closed
JCM
273
JS Capital Management
New York
– -$335K -12,200 Closed
AIM
274
Aigen Investment Management
New York
– -$291K -10,608 Closed
Nomura Holdings
275
Nomura Holdings
Japan
– -$275K -10,000 Closed
9 10
11
12 13

IOVA Hedge Fund Activity: Q3 2020 in Review

252 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2020, worth a combined $4.58B — up 18% from $3.88B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of IOVA and 46 opened new positions — a net loss of 5 holders — while 91 trimmed existing stakes and 83 added.

The largest buyer was ARK Investment Management, adding an estimated $112M. The largest seller was Perceptive Advisors, cutting an estimated $52.8M.

  • 252 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2020, down from 257 in Q2 2020.
  • Funds reported $4.58B of Iovance Biotherapeutics stock for Q3 2020, up 18% quarter-over-quarter.
  • 46 funds opened new Iovance Biotherapeutics positions in Q3 2020 and 51 closed out, a net change of -5 holders.
  • The largest Iovance Biotherapeutics buyer in Q3 2020 was ARK Investment Management, an estimated $112M added.
  • The largest Iovance Biotherapeutics seller in Q3 2020 was Perceptive Advisors, an estimated $52.8M sold.

Based on aggregated 13F filings for Q3 2020.